iData Insights

Glaucoma - Pipeline Review, H2 2015 Now Available at iData Insights

News   •   Jan 30, 2016 12:26 IST

This report provides comprehensive information on the therapeutic development for Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Glaucoma and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope

The report provides a snapshot of the global therapeutic landscape of Glaucoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Glaucoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Glaucoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Glaucoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Glaucoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Glaucoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Browse Complete Report with TOC

To Get Sample Copy of Report visit

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 9

Introduction 10

Global Markets Direct Report Coverage 10

Glaucoma Overview 11

Therapeutics Development 12

Pipeline Products for Glaucoma - Overview 12

Pipeline Products for Glaucoma - Comparative Analysis 13

Glaucoma - Therapeutics under Development by Companies 14

Glaucoma - Therapeutics under Investigation by Universities/Institutes 20

Glaucoma - Pipeline Products Glance 21

Late Stage Products 21

Clinical Stage Products 22

Early Stage Products 23

Unknown Stage Products 24

Glaucoma - Products under Development by Companies 25

Glaucoma - Products under Investigation by Universities/Institutes 32

Glaucoma - Companies Involved in Therapeutics Development 33

AC Immune SA 33

Acadia Pharmaceuticals Inc. 34

Advanced Refractive Technologies, Inc. 35

Aerie Pharmaceuticals, Inc. 36

Allergan Plc 37

Altacor Limited 38

Amakem NV 39

Asahi Kasei Pharma Corp. 40

AUS Bio Limited 41

Bausch & Lomb Incorporated 42

Bionure Farma, S.L. 43

Caladrius Biosciences, Inc. 44

Can-Fite BioPharma Ltd. 45

China Grand Wuhan General Pharmaceutical Research Institute 46

D. Western Therapeutics Institute, Inc. 47

DNAVEC Corporation 48

Dompe Farmaceutici S.p.A. 49

F. Hoffmann-La Roche Ltd. 50

Gene Signal International SA 51

Gilead Sciences, Inc. 52

Glaukos Corporation 53

GliaCure Inc. 54

Handok Inc. 55

Icon Bioscience, Inc. 56

IMMD Inc. 57

InMed Pharmaceuticals Inc. 58

Inotek Pharmaceuticals Corporation 59

InSite Vision Incorporated 60

Kadmon Corporation, LLC 61

Kala Pharmaceuticals, Inc. 62

Kukje Pharmaceutical Industry Co., Ltd. 63

Lacer, S.A. 64

Lee's Pharmaceutical Holdings Limited 65

Merck & Co., Inc. 66

Merz Pharma GmbH & Co. KgaA 67

Neurotech Pharmaceuticals, Inc. 68

NicOx S.A. 69

NoNO, Inc. 70

Ocata Therapeutics, Inc. 71

Ocular Therapeutix, Inc. 72

Oculis ehf 73

Ohr Pharmaceutical Inc. 74

Ono Pharmaceutical Co., Ltd. 75

Otsuka Holdings Co., Ltd. 76

Oxford BioMedica Plc 77

Quark Pharmaceuticals, Inc. 78

Quethera Limited 79

Regeneron Pharmaceuticals, Inc. 80

Sanofi 81

Santen Pharmaceutical Co., Ltd. 82

Senju Pharmaceutical Co., Ltd. 83

Shire Plc 84

SK Biopharmaceuticals Co., Ltd. 85

Sun Pharma Advanced Research Company Ltd. 86

Sylentis S.A. 87

ViSci Ltd. 88

vTv Therapeutics LLC 89

Glaucoma - Therapeutics Assessment 90

Assessment by Monotherapy Products 90

Assessment by Combination Products 91

Assessment by Target 92

Assessment by Mechanism of Action 97

Assessment by Route of Administration 101

Assessment by Molecule Type 103

Drug Profiles 105

(bimatoprost + brimonidine tartrate) - Drug Profile 105

(carteolol hydrochloride + latanoprost) - Drug Profile 106

(dorzolamide hydrochloride + latanoprost) - Drug Profile 107

(latanoprost + netarsudil mesylate) - Drug Profile 108

(latanoprost + trabodenoson) - Drug Profile 109

(tafluprost + timolol maleate) - Drug Profile 110

AC-262271 - Drug Profile 111

ACI-260 - Drug Profile 112

ACN-1052 - Drug Profile 113

aflibercept - Drug Profile 114

aganirsen - Drug Profile 117

ALT-022 - Drug Profile 119

ALY-1337 - Drug Profile 120

AMA-0076 - Drug Profile 121

Antibody to Inhibit Sema3A for Glaucoma and Optic Neuropathy - Drug Profile 122

Antisense Oligonucleotides to Inhibit P16INK4a for Primary Open-Angle Glaucoma (POAG) - Drug Profile 123

APH-1104 - Drug Profile 124

AR-13324 - Drug Profile 125

AR-13533 - Drug Profile 126

ATS-8535 - Drug Profile 127

BA-1049 - Drug Profile 128

BA-240 - Drug Profile 129

bamosiran - Drug Profile 130

bimatoprost - Drug Profile 132

bimatoprost - Drug Profile 133

bimatoprost SR - Drug Profile 134

BN-201 - Drug Profile 135

brimonidine tartrate - Drug Profile 136

CTI-085 - Drug Profile 137

DE-117 - Drug Profile 138

decorin - Drug Profile 139

Drug for Glaucoma - Drug Profile 140

Drug for Glaucoma - Drug Profile 141

Drugs for Steroid Induced Glaucoma - Drug Profile 142

Drugs to Inhibit Cadherin-5 for Glaucoma - Drug Profile 143

Drugs to Target Bestrophin-2 for Glaucoma - Drug Profile 144

GB-201 - Drug Profile 145

GB-202 - Drug Profile 146

GB-203 - Drug Profile 147

GB-204 - Drug Profile 148

GC-021109 - Drug Profile 149

Gene Therapy for Glaucoma - Drug Profile 150

Gene Therapy for Glaucoma and Retinitis Pigmentosa - Drug Profile 151

Gene Therapy for Ocular Diseases - Drug Profile 152

Gene Therapy for Steroid Induced Glaucoma and Ocular Hypertension - Drug Profile 153

Glaucoma-GT - Drug Profile 154

GS-607601 - Drug Profile 155

H-1129 - Drug Profile 156

HL-3501 - Drug Profile 157

HPP-851 - Drug Profile 158

IMD-1041 - Drug Profile 159

KJ-13003 - Drug Profile 160

KJ-14002 - Drug Profile 161

KL-00199 - Drug Profile 162

KR-12 - Drug Profile 163

LA-8045 - Drug Profile 164

latanoprost - Drug Profile 165

latanoprost - Drug Profile 166

latanoprost - Drug Profile 168

latanoprost - Drug Profile 169

latanoprost SR - Drug Profile 170

latanoprost SR - Drug Profile 172

latanoprostene bunod - Drug Profile 173

levobetaxolol hydrochloride - Drug Profile 175

lomerizine - Drug Profile 176

MD-920G - Drug Profile 177

MRZ-99030 - Drug Profile 178

NB-1111 - Drug Profile 179

NCX-1021 - Drug Profile 181

NCX-250 - Drug Profile 182

NCX-470 - Drug Profile 183

NCX-667 - Drug Profile 184

neurovitas - Drug Profile 185

NT-501 - Drug Profile 186

OC-201 - Drug Profile 189

OC-410 - Drug Profile 190

ONO-9054 - Drug Profile 191

OPA-6566 - Drug Profile 192

PBF-677 - Drug Profile 193

piclidenoson - Drug Profile 194

QPI-1007 - Drug Profile 196

R-801 - Drug Profile 198

R-807 - Drug Profile 200

Recombinant Protein to Agonize p75NTR and Trk for Ophthalmology - Drug Profile 201

RO-5093151 - Drug Profile 203

SAR-366234 - Drug Profile 204

SHP-639 - Drug Profile 205

SKL-G - Drug Profile 206

Small Molecule for Glaucoma - Drug Profile 207

Read More

About Us:

iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.

iData Insights

Tel: 1-866-237-2965


AboutiData Insights

We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future project.